Display options
Cite
Samuel G, Crow J, Klein JB, et al. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. Oncotarget. 2020;11(31):2995-3012doi: 10.18632/oncotarget.27678.
Samuel, G., Crow, J., Klein, J. B., Merchant, M. L., Nissen, E., Koestler, D. C., Laurence, K., Liang, X., Neville, K., Staggs, V., Ahmed, A., Atay, S., & Godwin, A. K. (2020). Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. Oncotarget, 11(31), 2995-3012. https://doi.org/10.18632/oncotarget.27678
Samuel, Glenson, et al. "Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers." Oncotarget vol. 11,31 (2020): 2995-3012. doi: https://doi.org/10.18632/oncotarget.27678
Samuel G, Crow J, Klein JB, Merchant ML, Nissen E, Koestler DC, Laurence K, Liang X, Neville K, Staggs V, Ahmed A, Atay S, Godwin AK. Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers. Oncotarget. 2020 Aug 04;11(31):2995-3012. doi: 10.18632/oncotarget.27678. eCollection 2020 Aug 04. PMID: 32821345; PMCID: PMC7415402.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2020 Aug 04;11(31):2995-3012. doi: 10.18632/oncotarget.27678. eCollection 2020 Aug 04.

Ewing sarcoma family of tumors-derived small extracellular vesicle proteomics identify potential clinical biomarkers.

Oncotarget

Glenson Samuel, Jennifer Crow, Jon B Klein, Michael L Merchant, Emily Nissen, Devin C Koestler, Kris Laurence, Xiaobo Liang, Kathleen Neville, Vincent Staggs, Atif Ahmed, Safinur Atay, Andrew K Godwin

Affiliations

  1. Division of Pediatric Hematology Oncology and Bone Marrow Transplantation, Children's Mercy Hospital, Kansas City, MO, USA.
  2. Department of Pediatrics, University of Missouri-Kansas City, Kansas City, MO, USA.
  3. University of Kansas Cancer Center, Kansas City, KS, USA.
  4. These authors contributed equally to this work.
  5. Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
  6. Clinical Proteomics Laboratory, Department of Medicine, University of Louisville, Louisville, KY, USA.
  7. Robley Rex VA Medical Center, Louisville, KY, USA.
  8. Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS, USA.
  9. Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  10. Biostatistics & Epidemiology Core, Children's Mercy Hospital, Kansas City, MO, USA.
  11. Department of Pathology, Children's Mercy Hospital, Kansas City, MO, USA.
  12. Bristol-Myers Squibb, Cambridge, MA, USA.

PMID: 32821345 PMCID: PMC7415402 DOI: 10.18632/oncotarget.27678

Abstract

PURPOSE: Ewing Sarcoma Family of Tumors (ESFT), the second most common pediatric osseous malignancy, are characterized by the pathognomonic chromosomal

MATERIALS AND METHODS: We performed the first high quality proteomic study of ESFT-derived sEVs from 5 ESFT cell lines representing the most common

RESULTS: From these analyses, two membrane bound proteins with biomarker potential were selected, CD99/MIC2 and NGFR, to develop a liquid-based assay enriching of ESFT-associated sEVs and detection of sEV mRNA cargo (

CONCLUSIONS: In this study, we demonstrate utilization of circulating ESFT-associated sEVs in pediatric patients as a source of minimally invasive diagnostic and potentially prognostic biomarkers.

Keywords: EWS-ETS; Ewing sarcoma; biomarkers; exosomes; extracellular vesicles

Conflict of interest statement

CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.

References

  1. Expert Rev Mol Diagn. 2019 Dec;19(12):1079-1088 - PubMed
  2. Biochem Pharmacol. 2012 Jun 1;83(11):1484-94 - PubMed
  3. Cell Mol Life Sci. 2018 Jan;75(1):1-19 - PubMed
  4. Talanta. 2013 Feb 15;105:80-6 - PubMed
  5. J Natl Compr Canc Netw. 2017 Feb;15(2):155-167 - PubMed
  6. J Clin Oncol. 2000 Jan;18(1):4-11 - PubMed
  7. Cancer Manag Res. 2018 Jan 09;10:49-60 - PubMed
  8. Mol Cell Proteomics. 2002 Nov;1(11):845-67 - PubMed
  9. BMC Cancer. 2012 Jan 17;12:22 - PubMed
  10. Nat Rev Immunol. 2002 Aug;2(8):569-79 - PubMed
  11. Nat Neurosci. 2002 Nov;5(11):1131-6 - PubMed
  12. Transl Neurodegener. 2017 Feb 2;6:3 - PubMed
  13. J Cancer Res Clin Oncol. 1987;113(2):187-91 - PubMed
  14. Oncotarget. 2017 Sep 1;8(43):75742-75755 - PubMed
  15. J Thromb Haemost. 2014 May;12(5):614-27 - PubMed
  16. J Clin Oncol. 2005 Jul 1;23(19):4354-62 - PubMed
  17. Cancer Genet. 2012 Jul-Aug;205(7-8):391-404 - PubMed
  18. J Mol Diagn. 2018 Jan;20(1):63-77 - PubMed
  19. Sci Rep. 2015 Jun 12;5:11295 - PubMed
  20. Cancer Treat Rev. 2002 Oct;28(5):255-71 - PubMed
  21. Adv Exp Med Biol. 2011;702:132-42 - PubMed
  22. Semin Immunopathol. 2011 Sep;33(5):419-40 - PubMed
  23. Semin Cancer Biol. 2003 Aug;13(4):275-81 - PubMed
  24. N Engl J Med. 1994 Aug 4;331(5):294-9 - PubMed
  25. Proc Natl Acad Sci U S A. 2011 Feb 8;108(6):2366-71 - PubMed
  26. Med Pediatr Oncol. 2003 May;40(5):276-87 - PubMed
  27. Crit Rev Oncog. 1996;7(1-2):89-100 - PubMed
  28. N Engl J Med. 2003 Feb 20;348(8):694-701 - PubMed
  29. Nat Med. 2015 Jul;21(7):827 - PubMed
  30. Curr Protoc Cell Biol. 2006 Apr;Chapter 3:Unit 3.22 - PubMed
  31. Biol Cell. 2013 Jul;105(7):289-303 - PubMed
  32. Sarcoma. 2011;2011:856190 - PubMed
  33. Br J Cancer. 2018 Aug;119(5):615-621 - PubMed
  34. BMC Bioinformatics. 2009 May 27;10:161 - PubMed
  35. J Mol Med (Berl). 2019 Jul;97(7):957-972 - PubMed
  36. Cancer Res. 2009 Mar 1;69(5):1776-81 - PubMed
  37. J Pediatr Hematol Oncol. 2008 Jun;30(6):425-30 - PubMed
  38. JAMA Oncol. 2016 May 1;2(5):608-615 - PubMed
  39. Eur J Cancer. 2008 Mar;44(5):699-709 - PubMed
  40. J Clin Oncol. 2012 Nov 20;30(33):4148-54 - PubMed
  41. Clin Exp Immunol. 2018 Jun;192(3):271-283 - PubMed
  42. PLoS Genet. 2014 Jul 10;10(7):e1004475 - PubMed
  43. Ann Oncol. 1998 Mar;9(3):275-81 - PubMed
  44. Pediatr Hematol Oncol. 2012 Feb;29(1):1-11 - PubMed
  45. Proc Natl Acad Sci U S A. 2014 Jan 14;111(2):711-6 - PubMed
  46. Oncologist. 2006 May;11(5):503-19 - PubMed
  47. Mol Cell Proteomics. 2018 Mar;17(3):495-515 - PubMed
  48. Lab Chip. 2014 Oct 7;14(19):3773-80 - PubMed
  49. Oncotarget. 2018 Apr 10;9(27):19006-19013 - PubMed
  50. Nat Med. 2012 Jun;18(6):883-91 - PubMed
  51. Int J Cancer. 2011 Mar 1;128(5):1139-50 - PubMed
  52. Nat Methods. 2009 May;6(5):359-62 - PubMed
  53. Nature. 2015 Jul 9;523(7559):177-82 - PubMed
  54. Lab Chip. 2018 Dec 4;18(24):3790-3801 - PubMed
  55. Hum Pathol. 2001 Sep;32(9):976-83 - PubMed
  56. Transl Res. 2018 Nov;201:136-153 - PubMed
  57. Ther Adv Med Oncol. 2018 Jun 01;10:1758835918774337 - PubMed
  58. Oncotarget. 2017 Feb 14;8(7):11917-11936 - PubMed
  59. Biochim Biophys Acta Proteins Proteom. 2019 Dec;1867(12):140203 - PubMed
  60. Cancer Res. 2011 Sep 15;71(18):5955-60 - PubMed
  61. Mol Clin Oncol. 2016 Dec;5(6):832-838 - PubMed
  62. Cancer Res. 2010 Feb 15;70(4):1668-78 - PubMed
  63. Biomark Med. 2013 Oct;7(5):769-78 - PubMed
  64. J Transl Med. 2011 Jun 08;9:86 - PubMed
  65. Cancer Discov. 2014 Nov;4(11):1326-41 - PubMed
  66. Cancer Discov. 2014 Nov;4(11):1342-53 - PubMed
  67. Oncotarget. 2017 Aug 4;9(2):1587-1601 - PubMed
  68. Blood. 1993 Nov 1;82(9):2605-10 - PubMed
  69. Front Immunol. 2014 Aug 11;5:383 - PubMed
  70. J Clin Oncol. 1997 Apr;15(4):1553-9 - PubMed

Publication Types

Grant support